Wealthfront’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
$320K Sell
2,965
-177
-6% -$19.4K ﹤0.01% 436
2018
Q2
$345K Sell
3,142
-225
-7% -$23.4K ﹤0.01% 418
2018
Q1
$338K Buy
3,367
+242
+8% +$24.8K ﹤0.01% 422
2017
Q4
$308K Sell
3,125
-57
-2% -$5.4K ﹤0.01% 425
2017
Q3
$298K Sell
3,182
-423
-12% -$44.9K ﹤0.01% 423
2017
Q2
$401K Buy
3,605
+281
+8% +$29.7K 0.01% 324
2017
Q1
$326K Buy
3,324
+221
+7% +$21.1K 0.01% 319
2016
Q4
$285K Buy
3,103
+354
+13% +$30.5K 0.01% 299
2016
Q3
$233K Buy
2,749
+127
+5% +$10.7K 0.01% 334
2016
Q2
$213K Buy
+2,622
New +$200K 0.01% 334
2015
Q4
Sell
-1,308
Closed -$80K 461
2015
Q3
$80K Sell
1,308
-528
-29% -$36.9K ﹤0.01% 444
2015
Q2
$133K Sell
1,836
-186
-9% -$13.7K 0.01% 348
2015
Q1
$155K Buy
2,022
+934
+86% +$66.9K 0.01% 297
2014
Q4
$73K Sell
1,088
-57
-5% -$3.6K ﹤0.01% 413
2014
Q3
$69K Buy
1,145
+561
+96% +$34.6K ﹤0.01% 353
2014
Q2
$35K Buy
584
+197
+51% +$11.5K ﹤0.01% 426
2014
Q1
$23K Buy
+387
New +$20.7K ﹤0.01% 406

Other funds holding DGX

Wealthfront's DGX Position: Q3 2018 in Review

Wealthfront reduced its Quest Diagnostics (DGX) stake by 5.6% in Q3 2018, selling an estimated $19.4K and leaving 2,965 shares worth $320K. The position accounts for ﹤0.01% of the portfolio, ranked #436.

Wealthfront first reported a position in DGX in Q1 2014 and has held it in 17 quarters since. The position peaked at $401K in Q2 2017. 674 funds tracked by Wall St. Rank hold DGX as of Q3 2018.

  • Wealthfront held 2,965 shares of Quest Diagnostics worth $320K as of Q3 2018.
  • Wealthfront sold 177 Quest Diagnostics shares in Q3 2018, an estimated $19.4K.
  • Quest Diagnostics made up ﹤0.01% of Wealthfront's portfolio in Q3 2018, its #436 holding.
  • Wealthfront first reported a position in Quest Diagnostics in Q1 2014 and has held it in 17 quarters since.
  • Wealthfront's Quest Diagnostics position peaked at $401K in Q2 2017.
  • 674 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2018.

Based on Wealthfront's 13F filing for Q3 2018, filed 13 Nov 2018.